Clinical response to oral tofacitinib in pediatric patients with alopecia areata
Soundos Youssef, Lindsey A. Bordone
Abstract
Alopecia areata (AA) is an autoimmune disease characterized by cytotoxic T cell–driven inflammation targeting hair follicles1,2 and causing nonscarring hair loss. AA is associated with the overexpression of proinflammatory cytokines acting via Janus kinase (JAK)/signal transducers and activators of transcription signaling pathway.1 AA disproportionately affects youth3 and carries a significant psychosocial burden.4 While a myriad of treatments has been used for AA with varying success, there is no cure.
Topics & Concepts
TofacitinibAlopecia areataMedicineJanus kinaseProinflammatory cytokineHair lossRuxolitinibJanus kinase inhibitorAlopecia universalisImmunologyDermatologyHair follicleKetotifenInflammationCancer researchInternal medicineRheumatoid arthritisCytokineMyelofibrosisBone marrowAsthmaHair Growth and DisordersImmune Cell Function and InteractionT-cell and Retrovirus Studies